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Experimental models that recapitulate mutational landscapes of human cancers are needed to decipher the
rapidly expanding data on human somatic mutations. We demonstrate that mutation patterns in
immortalised cell lines derived from primary murine embryonic fibroblasts (MEFs) exposed in vitro to
carcinogens recapitulate key features of mutational signatures observed in human cancers. In experiments
with several cancer-causing agents we obtained high genome-wide concordance between human tumour
mutation data and in vitro data with respect to predominant substitution types, strand bias and sequence
context. Moreover, we found signature mutations in well-studied human cancer driver genes. To explore
endogenous mutagenesis, we used MEFs ectopically expressing activation-induced cytidine deaminase
(AID) and observed an excess of AID signature mutations in immortalised cell lines compared to their
non-transgenic counterparts. MEF immortalisation is thus a simple and powerful strategy for modelling
cancer mutation landscapes that facilitates the interpretation of human tumour genome-wide sequencing
data.
H
igh-throughput sequencing has shown that cancer genomes are riddled with somatic alterations, with
numerous tumour types harbouring hundreds to thousands of mutations. Bioinformatic analyses of this
massive catalogue in search of recurring mutations have substantially contributed to the identification of
most of the genes functionally impaired in cancer development1. The genome-wide human cancer sequencing
data also provide a powerful resource for investigating the nature of mutagenic insults that give rise to mutations
in human population2,3. However, what is lacking in order tomake optimal use of this resource for such a purpose
is a suitable database of experimentally induced mutations to test inferences that come from inspecting human
mutation patterns. It is well known that mutagenic factors, whether chemical or enzymatic, mutate DNA in
characteristic ways, thereby revealing clues to their identities. This principle was elegantly demonstrated decades
before the advent of new sequencing technologies in a wide variety of assays4,5. These assays, however, had one
feature in common that limited their scope. Mutations were typically scored in a single gene (allowing clonal
selection), or at best, in a discrete number of specific genes. Although data from such experiments have been
fundamentally important to biology, the tests were not designed to recapitulate or interpret the more complex
mutation profiles generated from genome-wide data. Genome-wide sequencing of cells exposed to sources of
mutation in a controlled fashion will now allow more comprehensive experimental investigations of the muta-
genic activities of human carcinogens.
This study aims to determine whether a simple experimental system using in vitro immortalisation of normal
mammalian cells would generate genome-wide mutation data relevant to human tumours. Immortalisation of
primary cells, notably murine embryonic fibroblasts (MEFs), has been used extensively as a powerful in vitro
model for exploring genetic control of cellular homeostasis and its disruption in disease6. Recent research in this
area has shown that various molecular pathways that control cellular senescence and become circumvented in
vitro to allow cell immortalisation are cancer gene pathways, including oncogenes and tumour suppressor genes
known to bemutated in human cancer7–9. Encouragingly, we showed in previous work that when carcinogens are
applied to Hupki MEFs (MEFs carrying normal human p53 sequences embedded in the Trp53 gene, human p53
knock-in) prior to senescence, emerging clonal cell lines harbour TP53 gene signature mutations characteristic of
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the carcinogens and consistent with TP53 mutations detected in
human cancers from exposed patient cohorts10–12.
In the present study, we expanded this approach by assessing
exome-wide mutation patterns in the Hupki MEF immortalisation
assay (Supplementary Fig. 1). We sequenced the exome of immor-
talised MEF lines established from primary cultures exposed to well-
known carcinogens and compared the mutation profiles obtained in
these assays to those observed in genome-wide data from human
tumours with related aetiologies. Mutation signatures derived from
these assays were also compared to currently known signatures in
human cancers2. Since the MEF in vitro immortalisation process has
parallels with the conversion of normal cells to tumour cells in vivo,
we also investigated alterations in specific driver genes that could
provide mechanistic clues to molecular events governing senescence
bypass and immortalisation. Finally, in a proof-of-concept experi-
ment devised to explore an endogenous process proposed to contrib-
ute to the human mutation load, we examined the effect of
activation-induced cytidine deaminase transgene (AID-Tg) express-
ion on the pattern of base substitutions that accumulate during MEF
immortalisation13.
Results
Genome-wide mutation spectra from immortalised MEF cell
lines. Genomic DNA isolated from primary MEFs and from
immortalised cell lines derived from MEF cultures exposed to
aristolochic acid (AA), ultraviolet light subclass C (UVC), the
alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG),
the tobacco mutagen benzo(a)pyrene (BaP), or unexposed cultures
(see Supplementary Table 1), were subjected to genome-wide
mutation profiling by whole-exome sequencing (WES) (see
Supplementary Fig. 1 for assay overview and Methods for WES
data processing and analysis). Two cell lines per exposure category
were investigated. As shown in Fig. 1, the patterns of mutations
found in the MEF cell lines were in marked concordance with
those observed in human tumours with aetiologies related to the
mutagens tested, and were as expected from previous knowledge
on the mutagenic properties of these particular exposures. In the
cell lines derived from AA-exposed cultures, the most frequent
type of mutation was A:T . T:A as in urinary tract urothelial
cancers (UTUC) from AA exposed patients (Fig. 1a), and a
significant strand-bias towards the non-transcribed strand was
observed for A . T (Table 1), in keeping with previous reports on
human UTUC fromAA-exposed patients14,15. In cell lines from BaP-
exposed cultures, the most frequent type of mutation was C:G.A:T
with a strand bias towards the non-transcribed strand for G. T as is
seen in lung cancers (Lung_Ca) from heavy smokers (Fig. 1b and
Table 1). In cell lines from MNNG-exposed cells, the most frequent
mutation type was C:G.T:Awith no significant strand-bias (Fig. 1c
and Table 1), consistent with the alkylating properties of this agent
and with the pattern observed in brain tumours from patients treated
with the alkylating agent temozolomide. In the cell lines from UVC-
exposed cultures, themost frequent type ofmutation was C:G.T:A,
as in skin squamous cell carcinomas (Skin_SCC), and with a strand-
bias of borderline significance (Fig. 1d and Table 1).
In addition to exogenous exposures, we assessed the effect of an
endogenous mutagenic process by analysing immortalised MEFs
harbouring a transgene expressing activation-induced cytidine dea-
minase (AID) (see Methods). In these cell lines, referred to as
HxAID-Tg, a predominance of C:G. T:A transitions was observed
(Fig. 1e), as expected from experimental studies on the mutagenic
properties of AID13,16. Finally, four immortalisedMEF cell lines from
untreated cultures were analysed to determine underlying mutagen-
esis in this model. Interestingly, the most predominant mutation
type was C:G . G:C (Fig. 1f) in all four cell lines, as has been
observed previously in the Trp53 gene of immortalised MEFs17.
The sequence context of mutations is an important feature of
mutation patterns because many mutagenic agents and processes
exhibit a preferred base context. We analysed the 59 and 39 base
context of mutations in all conditions described above. As shown
in Fig. 1, a previously described preferred sequence context for
each specific exposure was recapitulated in the MEF assay. Indeed,
A:T . T:A mutations occurred predominantly within a 59-CAG-39
motif, as in the selected human set (Fig. 1g) and as reported in other
published series14,15,18-20. For BaP exposure, C . A mutations
occurred most frequently in 59-CCN-39 triplets (corresponding to
59-NGG-39 for the complementary G . T), as in the human
lung tumour dataset (Fig. 1h). In cell lines from MNNG cultures,
C . T transitions with a C or T in 39 and any base in 59 were the
most frequent (corresponding to 59-(G/A)GN-39 for the comple-
mentary G.Amutations), observed also in recurrent glioblastomas
of temozolomide-treated patients (Fig. 1i). These mutations
occurred mainly outside CpG sites as expected. In the cell lines
derived from UVC treated MEF cultures, C . T changes within a
59-(C/T)CN-39 motif were the major events as seen in human skin
SCC (Fig. 1j). This context is expected from the published literature
on UVmutagenesis, which describes the highly characteristic altera-
tions at pyrimidine dimers induced by UV exposure. Interestingly,
the frequent C . G mutations found in the spontaneous lines
showed a preferred sequence context for 59-GCC-39 a signature that
was also present, although much less prominently, in most of the
other cell lines (Fig. 1l). Finally, in the spontaneously immortalised
lines from HxAID-Tg MEFs (Fig. 1k) the predominant C . T
changes were most frequently observed in a 59-GC(A/C/T)-39
sequence context, followed by 59-AC(A/C/T)-39. These findings
match the preferred contexts previously demonstrated for AID
activity21,22. The most frequent single base substitutions (SBS)
observed in human cancers and in mammalian evolution are
C. T transitions at 59-NCG-39 sites (CpGs). These mutations occur
following spontaneous deamination of 5-methyl-cytosines and result
inC.T transitions23. In the cell lines analysed here, CpGs accounted
for 25–30% of the C. Tmutations in the cell lines derived fromAA,
BaP and untreated MEF cultures, but for less than 15% of C . T
mutations in the MNNG, UVC or HxAID-Tg cell lines, which is
consistent with the treatment-specific sequence context of C . T
transitions in these latter cell lines.
Two types of statistical analyses were then applied to these data
(Fig. 2). Firstly, principal component analysis (PCA) was performed
to assess whether global mutation patterns obtained in the MEF
immortalisation assays can distinguish between cell lines obtained
from different treatments/conditions. Using percent frequency
values of the six mutation types in their triplet sequence context
(amounting to a total of 96 variables), the two first components
were able to discriminate the replicate cell lines according to each
specific treatment condition (Fig. 2a). When including the human
cancer datasets in the exposure model, we observed a good concord-
ance with the mouse datasets for most conditions, with the exception
of the UVC treatment which showed a broader confidence interval
(Fig. 2b). Secondly, themethod used by Alexandrov et al.24, to extract
signatures was adapted and applied to the 14 cell line data (see
Methods). Although this method is optimized for large datasets, it
could identify six signatures that corresponded to the six experi-
mental conditions (Supplementary Fig. 2) andwere concordant with
the mutation patterns shown in Fig. 1. The comparison of the MEF
experimental signatures with the 27 human-cancer derived signa-
tures reported by Alexandrov et al.2, showed high similarity between
the MNNG signature and Signature 11 (temolozomide), similarity
between the BaP signature and Signature 4 (smoking), and between
AID signature and Signature 19 (not identified) (Fig. 2c). No sim-
ilarity was found for the AA signature (patients with AA-associated
tumours were not analysed by Alexandrov et al.), or for the signature
observed in the spontaneous immortalised cell lines.
www.nature.com/scientificreports
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Figure 1 | Mutation patterns derived from exome data obtained from MEF immortalised cell lines. Mutation type distributions (a–f) and sequence
context (g–l) of single base substitutions. For each treatment condition, data are shown for two independent immortalised cell lines and for a set of human
tumours related to the tested condition. In (a–f), the percentage of each substitution type is shown with the total number of mutations indicated in
parentheses. In (g–l), heat maps of mutation sequence context are shown. The percentage of each substitution type within a triplet sequence context is
colour-coded according to the percent values. Highly abundant mutations are represented in red and low abundance mutations are in yellow. (a,g)
Aristolochic-acid treatment (two left panels) and upper urinary tract human tumours (right panel) from patients exposed to AA. (b,h) Benzo(a)pyrene
treatment (two left panels) and lung adenocarcinomas (right panel) from heavy smokers. (c,i) N-methyl-N’-nitro-N-nitrosoguanidine treatment (two
left panels) and human recurrent glioblastoma treatedwith temozolomide (right panel). (d,j) UVC treatment (two left panels) and human skin squamous
cell carcinomas (right panel) (COSMIC v65). (e,k) AID transgene (two panels). (f,l) Data from four independent cell lines obtained by spontaneous
immortalisation of the Hupki MEF primary cells (Spont, no treatment).
www.nature.com/scientificreports
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These results show that mutation patterns obtained in the MEF
immortalisation assay are specific to the exposure and can reveal
carcinogen-specific signatures that are relevant to human cancers.
Driver gene mutation status in immortalised MEF cell lines. The
cell lines from carcinogen exposure experiments chosen here for WES
studies harbour TP53 mutations that arose during immorta-
lisation of the primary cells. To investigate whether other cancer
driver genes were recurrently affected during the senescence bypass/
immortalisation process, we analysed the mutation status of other
established or putative cancer drivers, including all those defined as
oncogenes or tumour suppressor genes according to the ‘‘20/20 rule’’
formulated by Vogelstein et al.1, as well as genes encoding regulators
of the epigenome that have been described as a newly emerging class
of cancer driver genes1,25,26. Non-synonymous and truncating
mutations found in these selected driver genes are detailed in
Supplementary Dataset 1 and graphically summarized in
Supplementary Dataset 2. A number of genes in these functional
classes were found altered by mutations characteristic of the
exposure that cells underwent prior to immortalisation. Although
most genes were mutated only in one line, the Ep400, Dnmt1,
Kdm6b, Kmt2d, Arid1b and Arid2 genes were mutated in at least
two lines. Ep400 and Kmt2d in particular were mutated in four cell
lines. Ep400, a regulator of cellular senescence within the p53-p21
axis27, was affected by a truncating mutation in one line, and
Kmt2d carried three mutations in important functional domains.
The most unequivocal driver gene mutations were two activating
Ras missense mutations, highly recurrent in human cancers: the
(c.A182T/p.Q61L) Hras1 mutation in one AA cell line
corresponding to the HRAS mutation previously associated with
exposure to AA in humans and animal models14,18,28–30, and an
activating mutation in the Kras oncogene (c.A182G/p.Q61R)
identified in one of the UVC lines. Overall, these observations
suggest that the MEF immortalisation assay captures and selects for
driver gene mutations relevant to cancer biology, and are in keeping
with extensive literature on the impact of cancer-related genes on
senescence bypass, immortalisation and transformation of MEFs9,31.
Discussion
In this report we show that mutations acquired in MEFs during
establishment in culture and studied at the exome level reveal
patterns relevant to human cancers. While theMEF immortalisation
assay protocol has been shown previously to recapitulateTP53muta-
tion patterns in the context of specific carcinogen exposures10,11, we
demonstrate here that this assay is highly suitable as a selection
strategy to obtain a cell population harbouring a suite of base sub-
stitutions relevant to exome-wide mutation data derived from
human cancers. In principle, one single immortalised cell line pro-
vides information to identify a mutation signature, whereas many
cell lines would be necessary when interrogating a single gene such as
TP53. In practice, of course, WES on multiple cell line replicates per
exposure or condition is warranted and will be called for in extended
studies in the future to generate highly robust mutation signatures.
The scope of overlap between mutation patterns in human datasets
and immortalised MEF lines includes: (a) the global distribution of
mutation types, (b) the accumulation of mutations on the non-tran-
scribed strand (strand bias) for treatments with carcinogens known
to elicit transcription-coupled DNA repair, and (c) the sequence
context of the dominantmutation type. Thus, using four carcinogens
with well-known mutagenic properties, the predominant mutation
signatures we found with this model for the four tested carcinogens
were the ones expected for these mutagenic agents. Although we
analysed only two cell lines for each carcinogen, the expected signa-
tures were evident in single cell lines and were highly reproducible
between the two cell lines. The human tumour datasets used for
comparison with our in vitro data were selected from publicly avail-
able data and our selection was based on whether the suspected
aetiologies of the tumour sets were linked to the carcinogen tested
in MEFs. The most striking matching condition was the AA treat-
ment. In both human and in vitroMEF data, over 50% of mutations
were A. T transversions, with a significant strand bias of 251 and a
sequence context dominated by 59-CAG-39. The aetiology of the
tumours included in the human set has been clearly associated with
the AA exposure14. Since AA is a potent carcinogen that mainly
causes A. T transversions, enrichment of these somatic mutations
in exposed individuals is likely to reflect the insult of AA exposure.
The AA signature has not been found in any other cancer type so
far32. In the case of the in vitroWES data from cell lines arising from
MNNG-exposed cultures, the human set chosen for comparison
consisted of patients treated with the drug temozolomide, which, like
MNNG, is an alkylating agent. The global mutation type distribution
was strikingly similar between the mouse and human data and very
distinct from primary tumours of the same type but not exposed to
temozolomide (Supplementary Fig. 3). The MNNG signature was
Table 1 | Significance of the mutation strand bias for all mutation types in each experimental condition (ratio of the number of mutation on
the non-transcribed to transcribed strand and FDR q-values for significance)
SBS type Condition AA BaP MNNG UVC HxAID-Tg Spont
A:T . C:G
Ratio 1.0 1.1 1.1 1.0 1.0 1.4
FDR-q 1.000 0.881 1.000 1.000 1.000 0.277
Significance - - - - - -
A:T . G:C
Ratio 1.3 1.0 1.0 1.0 0.8 0.9
FDR-q 0.591 1.000 1.000 1.000 0.805 1.000
Significance - - - - - -
A:T . T:A
Ratio 2.1 1.5 0.5 1.1 1.1 1.6
FDR-q ,10–18 0.038 0.277 1.000 1.000 0.147
Significance *** * - - - -
C:G . A:T
Ratio 0.9 0.6 0.7 0.8 1.0 1.0
FDR-q 1.000 ,10–9 0.707 0.796 1.000 1.000
Significance - *** - - - -
C:G . G:C
Ratio 1.0 0.9 0.7 0.8 1.1 1.0
FDR-q 1.000 0.805 0.796 0.796 0.948 1.000
Significance - - - - - -
C:G . T:A
Ratio 2.2 1.1 1.0 1.3 1.0 1.1
FDR-q ,10–3 0.805 0.796 0.026 1.000 0.796
Significance *** - - * - -
Significance: * q , 0.05; ** q , 0.01; *** q , 0.001.
www.nature.com/scientificreports
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also very similar to the temozolomide signature derived from
another set of temozolomide-exposed patients reported previously2.
This signature is thus highly specific for alkylating agents such as
MNNG and temozolomide. With respect to other exposures, it is
clear that human tumour development typically involves various
mutational mixtures and selection processes, resulting in a complex
picture of mutation signatures. These considerations may explain
why the tumour data from lungs of heavy smokers differ from the
Figure 2 | Analysis of mutation signatures derived from exome data obtained from MEF immortalised cell lines. (a) Principal component analysis
(PCA) of WES data using mutation signatures. PCA was computed using as input the frequency matrices of sequence context mutations (96 variables)
from cell lines immortalised following exposure of primary HupkiMEFs to a carcinogen (AA, BaP,MNNGorUVC), fromHupkiMEFs carrying the AID
transgene (HxAID-Tg) or from Hupki MEF-derived cell lines that immortalised spontaneously (Spont). Each sample is plotted considering the value of
the first and second principal components (PC1 and PC2). The percentage of variance explained by each component is indicated within brackets in each
axis. A 95% confidence ellipsis is drawn for each experimental condition and the empty squares indicate the respective centre of gravity. Cells and samples
are represented by round and squared solid symbols, respectively. (b) Same as in (a) but with the human tumour datasets (same as shown in Figure 1)
added to the input and labelled by arrows. HxAID-Tg samples are omitted in (b) as no corresponding relevant tumour data were identified. AAN_UTUC,
aristolochic acid nephropathy-related upper urinary tract urothelial carcinoma; GBM_TZM, glioblastoma after temozolomide treatment; Lung_Ca, lung
carcinoma; Skin_SCC, skin squamous cell carcinoma. (c) Graphical representation of the similarity distance of each of the sixMEF signatures (front-back
axis) to each of the 27 human cancer signatures2 (horizontal axis, 1A through U2). The vertical axis measures the similarity of signatures between the two
systems, expressed as negative log(tan(angle), see Methods. Negative values below the x-z plane correspond to angles.45u and represent dissimilarity,
and are thus not shown.
www.nature.com/scientificreports
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in vitro data from BaP exposure with respect to the less prominent
mutation types. Tobacco smoke contains a highly complex mixture
of carcinogens. Nevertheless, the BaP signature derived from the in
vitro assay exhibited similarity with the human tumour-derived
smoking signature reported previously2, suggesting that BaP and
possibly other smoke components that have similar mutagenic prop-
erties constitute one of the main carcinogenic insults responsible for
the smoking signature observed in human tumours. The dataset
from tumours associated with UV exposure was the most distant
from the signature obtained in vitro, although the expected C . T
mutations within a 59-(C/T)CN-39 context were prominent in both
sets. There are several possible explanations, such as the technical
aspects of the experimental procedure in vitro, or the mutagenic
activities of sunlight compared to UVC alone. These results are
reflected in the principal component analysis that showed the closest
relationship between human and MEF data for AA and BaP and a
more distant relationship for UVC. In addition to exogenous expo-
sures, the spontaneous decay of DNA is a well-known cause of the
human mutation load33 and the deregulation of endogenous cellular
enzymes that accelerate the accumulation of sequence changes is
becoming of increasing interest to cancer biologists. It is a consid-
erable challenge, however, to determine the relative contributions of
different DNA metabolism pathways to genetic alterations observed
in human cancers, and to understand the factors that may result in
the deregulation of normal processes governing DNA integrity.
Recently the APOBEC/AID families of cytidine deaminases have
come under scrutiny because of their potential roles in cancer as
endogenous sources of mutation in various cancer types2,34,35. AID,
which is normally expressed in B-lymphocytes, has been proposed as
a possible source of mutagenic activity in the development of various
inflammation-associated cancer types when expressed inappropri-
ately36,37. An early investigation on mutation patterns produced by
AID in a single reporter gene showed a strong C . T mutation
signature as anticipated16, and there are now many studies exploring
the impact of ectopic AID expression on cancer development13. Here
we compared the sequence changes during immortalisation of MEFs
harbouring a constitutively active AID transgene withMEFs that did
not carry the transgene. The AID signature mutation was easily
captured by this strategy, providing a proof-of-concept demonstra-
tion of the applicability of this approach to investigating endogenous
mutagenesis. Interestingly, the in vitro AID signature showed some
similarity with one of the signatures found in pilocytic astrocy-
toma2,34,35, but was not represented in other cancer types and had
no similarity to two previously reported APOBEC signatures2,34,35.
The full role of AID in shapingmutation patterns in humans remains
to be investigated.
Surprisingly, the analysis of spontaneously immortalised cell lines
from untreated cultures showed a strikingly high frequency of C.G
mutations in the 59-GCC-39 sequence context, also present (albeit at
lower and variable frequency) in all cell lines (Fig. 1 and
Supplementary Fig. 2). A high frequency of C . G mutations in
the p53 gene was observed previously in both Hupki MEFs (with
human TP53 sequences) and MEFs with the murine Trp53 gene17.
Our WES results show that this phenomenon is global and may be
due to specific mutagenic pressures inherent to the experimental
conditions. GeneOntology Biological Process analysis of genes affec-
ted by non-synonymous C . G mutations in the spontaneously
immortalised cell lines identified 11 genes involved in regulation of
apoptosis/programmed cell death (GO 0042981; GO 0043067) as
high scoring categories (enrichment p-value , 0.05, Fisher’s exact
test, Supplementary Table 2), a finding consistent with the cultures
overcoming senescence, and with individual cells acquiring immor-
talised properties. This signature did not show any similarity to those
reported by Alexandrov et al.2. Although C.Gmutations have been
associated with two signatures linked to APOBEC activity in human
cancers2, they occur in a different sequence context of 59-TCA-39. A
recent genome-wide analysis of gingivo-buccal oral SCC from Indian
patients reported a high frequency of C.Gmutations (although the
sequence context was not reported) in three tobacco users carrying a
high mutation load in their tumours38. These authors proposed that
the unexpectedly high numbers of C. G mutations in their sample
set may be caused by oxidative damage. The DNA lesion 8-oxogua-
nine caused by exposure to reactive oxygen species39,40 can lead to this
transversion. The elevated numbers of C. G substitutions in spon-
taneously immortalising MEFs may be a cell culture artefact caused
by high oxygen levels of standard incubation conditions, and cultur-
ing the cells at physiological levels of oxygen can test this premise.
Further investigation of the origin of these C.G substitutions in the
MEF in vitro assay is warranted.
Although the number of cell lines analysed in the present study is
limited, we identified several recurrently mutated genes among
oncogenes and tumour suppressor genes classified as cancer drivers,
or regulators of the epigenome, an emerging new class of potential
driver genes. We note, however, that most of these mutations are
likely to be passenger events occurring in the MEF immortalisation/
transformation process, analogous to observations in human can-
cers. Interestingly, while mutations in all categories of genes but
histone genes were observed in the carcinogen-exposed lines, the
HxAID-Tg cell lines accumulated mutations mainly in histone genes
(SupplementaryDatasets 1 and 2). A study to explore the reasons for
this observation will require larger numbers of immortalised cell
lines both with and without the AID transgene. The p53 status of
emerging immortalised cells may also influence the subset of target
genes subsequently mutated and selected for, but again, to address
this speculation properly, an extensive set of cell line replicates will be
needed.
Exome-wide analysis of MEFs thus joins epigenetic profiling and
senescence bypass screens in the modern assembly of in vitro tools to
elucidate cancer biology9,41. Analysis of more cell lines and detailed
functional analyses of the specific mutations will be important in
order to distinguish driver from passenger mutations in WES-MEF
studies in a robust, statistically soundmanner. Analysis of indels will
be considered in future studies with more cell line replicates as the
number of indels called in the current sample set was too small to
derive meaningful interpretations of how indels might contribute to
particular mutational signatures. The analyses of indels might also
provide a more complete picture of mutations in tumour suppressor
genes as this type of cancer gene is more often altered by indels. The
present study is limited to a small number of cell lines, and these have
acquired typical human tumour TP53 mutations during immortali-
sation. The p53 gene mutation is the most common specific altera-
tion known to drive senescence bypass and immortalisation of
MEFs42,43. It will be interesting to investigate to what extent the
p53 status influences global mutation patterns and the subset of
mutated driver genes by comparing WES data from cell lines retain-
ing the wild-type p53 gene sequence with cell lines that have acquired
p53 mutations typical of human tumours.
In summary, the present study demonstrates the potential of the
MEF immortalisation assay to reveal mutation signatures of human
carcinogens. Although the use of mouse cells can be seen as a lim-
itation because of differences in metabolism and DNA repair
between humans and mice, in vitro cell models offer various strat-
egies to accommodate or even exploit these distinctions, such as
the addition of human liver microsomes to the culture, or breeding
of mice with transgenic or knock-in strains expressing human
genes to investigate various parameters relevant to a particular can-
cer risk factor. The ability of the MEF immortalisation model to
recapitulate human carcinogen mutation signatures observed from
whole-genome analysis of human tumours suggests that the model
can provide important clues about the involvement of potential car-
cinogens in instances where aetiological and mechanistic evidence is
deficient.
www.nature.com/scientificreports
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Methods
HupkiMEF cell lines. This study included immortalised MEF cell lines derived from
primary cultures exposed to carcinogens that were reported previously
(Supplementary Table 1 and references therein). They were generated following a
procedure referred to in the literature as the 3T3 protocol44, with minor adaptations.
Briefly, fibroblasts from 13.5-day old Trp53tm/Holl mouse embryos harbouring a
knock-in humanised version of the p53 gene (Hupki MEFs) were seeded into six-well
plates, exposed to cancer agents or solvent during early passages, and maintained in
culture with occasional passaging until cultures emerged from senescence.
Immortalised cultures were passaged at low density for several passages thereafter,
prior to screening for the presence of a heterozygous or homo/hemizygous TP53
mutation, and their designation as established cell lines. Cell lines chosen for the
present analysis had acquired a dysfunctional TP53mutation during immortalisation
(Supplementary Table 1). Acquisition of Trp53 gene mutations frequently occurs
during senescence bypass and establishment in culture10,17,42,43 providing a convenient
way to assess the identity and clonal origin of the immortalised cultures.
Cell lines with the AID transgene were established for the present study by crossing
Hupki mice45,46 with AID transgenic mice47. From the interbred colony, we harvested
MEFs from embryos homozygous for the (non-mutated) knock-in TP53 allele and
either with or without the transgene (referred to as HxAID-Tg and MEFs respect-
ively). T12.5 flasks (6 per MEF genotype) were seeded with 53 104 cells and cultured
until the cells emerged from senescence, regained uniform morphology, and could
sustain repeated passaging at .1510 dilution. Genomic DNAs from two immorta-
lised cell lines per condition (independent biological duplicates) were prepared for
WES analysis.
DNA preparation andWES.Genomic DNA (gDNA) was extracted from cells using
DNeasy blood and tissue kit (QIAGEN) and checked for purity, concentration, and
integrity by OD260/280 ratio using NanoDrop Instruments (NanoDrop
Technologies, Wilmington, DE, USA) and agarose gel electrophoresis. DNA was
sheared by fragmentation by Covaris (Covaris, Inc., Woburn, MAUSA) or Bioruptor
(Diagenode, Inc., Denville, NJ, USA) and purified usingAgencourt AMPure XP beads
(Beckman Coulter, Fullerton, CA, USA). DNA samples were then tested for size
distribution and concentration using an Agilent Bioanalyzer 2100 or Tapestation
2200 and by OD260/280 ratio. Fragment ends were repaired and Illumina libraries
were generated using NEBNext reagents (New England Biolabs, Ipswich, MA, USA).
Libraries were then subjected to exome enrichment using SureSelect XT Mouse All
Exon Kit (Agilent Technologies, Wilmington, DE USA) following manufacturer’s
instructions. Enrichment was verified by qPCR and the quality, quantity and
fragment size distribution of DNA determined by an Agilent Bioanalyzer or
Tapestation. The libraries were sequenced in paired-end 100 nucleotide (nt) reads
using the Illumina HiSeq2500 platform according to manufacturer’s protocols.
MEF whole-exome data processing. All FASTQ files were analysed with FastQC to
check sample homogeneity and quality. The FASTQ sequences were next aligned to
the mm9 mouse reference genome with Burrows-Wheeler Aligner (BWA, version
0.7.5a) and the resulting SAM file was sorted and compressed in BAM format using
Picard SortSam (version 1.98). Duplicate reads in the resulting BAM files were flagged
with PicardMarkDuplicates. Local realignment around indels was performed in three
steps: firstly, creation of a table of possible indels using GATK (version 2.7-2)
RealignerTargetCreator, secondly, realignment of reads around those targets with
GATK IndelRealigner, and lastly a correction of mate pair information was done
using Picard FixMateInformation. The base quality score recalibration required two
steps: first to generate a recalibration table with GATKBaseRecalibrator, then to print
reads based on the previous table with GATK PrintReads. An average of 58.8 million
reads (100 bp)were sequenced per sample, of which 98%weremapped, 77% on target
with a mean coverage of 61 (see Supplementary Table 3 for detailed metrics of
sequencing quality and coverage). The recalibrated BAM files were used to call
variants with MuTect software (version 1.1.4) using default parameters (including
reads quality .20 and calls made only if the position has at least 14 reads in the
tumour sample and at least 8 reads in the normal sample). As MuTect is tuned to
perform normal/tumour comparison, primary cell cultures were used as ‘‘normal’’
samples and immortalised cell lines as ‘‘tumour’’ samples. Each immortalised cell line
was compared to two primaryMEF cultures and only the overlapping calls were taken
into consideration to maximize the chance of robust variant calls and to exclude
potential polymorphisms.
Human genome-wide sequencing datasets. Publicly available somatic mutation
data obtained from whole-genome or whole-exome sequencing of human tumours
were retrieved from the Catalogue Of Somatic Mutations In Cancer (COSMIC)
database or original papers (selecting only SBS): a set of 14,715 substitutions reported
in 19 UTUC samples from AA-exposed patients14; a set of 6,066 substitutions
observed in seven primary skin squamous cell carcinomas (COSMIC v67); a set of
3,026 mutations observed in 10 primary lung adenocarcinomas from heavy
smokers48; a set of 10,455 mutations observed in eight glioblastomas recurring in
patients treated with temozolomide49; a set of 288 mutations observed in eight
primary astrocytomas49; and a set of 378 mutations observed in four primary
glioblastomas50.
Annotations of mutation data. For all datasets (MEF and human sets), the
chromosome number, genomic coordinates, reference and mutated nucleotides were
extracted for each variants. Variants were annotated with AnnoVar (version
2013aug23) using refGene, knownGene, ensGene, cytoBand, genomicSuperDups,
and dbSNP128 databases for the mm9 mouse genome build. The human sets were
annotated using additional databases: gwasCatalog, 1000 Genomes Project, NHLBI
GO Exome Sequencing Project (ESP), COSMIC, dbSNP137 (hg19 build), and
PolyPhen and SIFT databases for predicting the functional impact ofmutations. Gene
strand orientation was retrieved from the UCSC Genome Browser database using a
Perl script developed by Heng Li at the Sanger Institute. Mutations were included in
the analyses only if they could be successfully annotated. Variants present in the
dbSNP128 polymorphism database were excluded. The comprehensive lists of all SBS
identified in allMEF conditions and SBS fromhuman tumour datasets are available as
Supplementary Dataset 3.
Functional annotation analysis. A comprehensive list of established cancer driver
genes (oncogenes and tumour suppressor genes) and candidate drivers coding for
modifiers of DNA, histones and regulators of chromatin structure was assembled
from literature and somaticmutation databasemining1,25,26. Selected gene classes were
annotated with functional domain information obtained from the UniProt and
ENSEMBL databases. The comprehensive list of functional gene classes was matched
against genes withmutations found in allMEF cell lines. Non-synonymouslymutated
genes were further selected, considering both exposure-specific alterations and any
other mutation type. Human orthologues of the selected genes were examined in the
COSMIC database for frequency of mutations in human tumours. For oncogenes,
positions corresponding to non-synonymous mutations in MEFs were identified in
human orthologues and investigated for mutation status in the COSMIC database.
Gene Ontology Biological Process analyses were performed with the NIH DAVID
web tool using default settings.
Statistical analyses. Statistical analyses were performed using the free R software (R
Core Team, 2013) v3.0.2 or Excel. For the strand bias analyses, the statistical
difference in the number of SBS between the non-transcribed and the transcribed
strand was evaluated through the Pearson’s x2 test, using the prop.test function
available in the stats R package. The test evaluated, for each experimental condition,
whether the proportions of SBS in the non-transcribed strand differed from 0.5,
which is the expected value by chance. As multiple conditions were assessed in
parallel, a false discovery rate (FDR) correction was applied using the p.adjust
function from the stats R package.
For analyses of mutation signatures, mutations were classified into 96 types
determined by the six possible substitutions (A:T . C:G, A:T . G:C, A:T . T:A,
C:G. A:T, C:G. G:C, C:G. T:A) and the 16 combinations of flanking (59 and 39)
nucleotides. First, a PCA analysis was performed using as input the 96 variables. A
95% confidence interval was computed, including either only MEF samples or MEF/
human data, to define the limits on the PCA plot for each experimental condition.
Such analysis was performed based on the available functions in the FactoMiner
package available in the Bioconductor repository (R package version 1.25. http://
CRAN.R-project.org/package5FactoMineR). Second, the catalogue of experimental
mutations defined by their 96 types was decomposed into signatures using the non-
negative matrix factorisation algorithm of Brunet with the Kullback-Leibler diver-
gence penalty24,51. The number of signatures was pre-set to six (the expected number
of signatures based on the number of conditions) but the process was otherwise
unsupervised: no information regarding exposures was used for the extraction of the
signatures. To evaluate the similarity between the signatures from the cell lines and
from human tumours by Alexandrov et al.2,24, each signature was represented as a
vector in 96-dimensional space. The tangent of the angle between each pair of vectors
was taken as the distance metric: the tangent transformation serving to expand the
scale to compensate for the geometry of high-dimensional space. This distance was
used to compute the grid of distance from each of the sixMEF signatures to each of the
27 human signatures and converted for presentation to a similarity matrix by taking
the negative log of the distance with negative values (angles .45u) suppressed.
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